FDA Approved Drugs for Rheumatology

FDA Approved Drugs for Rheumatology

Drugs Approved in 2019

Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019

Rinvoq (upadacitinib); AbbVie; For the treatment of rheumatoid arthritis, Approved August 2019

Drugs Approved in 2018

Olumiant (baricitinib); Eli Lilly; For the treatment of moderate to severe rheumatoid arthritis with inadequete response to TNF antagonist therapies, Approved May 2018

Drugs Approved in 2017

Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017

Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017

Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017

Drugs Approved in 2016

Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016

Drugs Approved in 2014

Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014

Drugs Approved in 2013

Actemra (ocilizumab); Genentech; For the treatment of Polyarticular Juvenile Idiopathic Arthritis, Approved May 2013

Cimzia (certolizumab pegol); UCB; For the treatment of active psoriatic arthritis, Approved September 2013

Cimzia (certolizumab pegol); UCB; For the treatment of active ankylosing spondylitis , Approved October 2013

Ilaris (canakinumab); Novartis; For the treatment of Systemic Juvenile Idiopathic Arthritis, Approved May 2013

Drugs Approved in 2012

Rayos (prednisone) delayed-release tablets; Horizon Pharma; For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions, Approved July of 2012

Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012

Xeljanz (tofacitinib); Pfizer; For the treatment of moderately to severely active rheumatoid arthritis, Approved November 2012

Drugs Approved in 2011

Actemra (tocilizumab); Genentech; For the treatment of systemic juvenile idiopathic arthritis, Approved April 2011

Duexis (ibuprofen and famotidine); Horizon Pharma; For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers, Approved April 2011

Drugs Approved in 2010

Actemra (tocilizumab); Genentech; For the treatment of rheumatoid arthritis, Approved January 2010

Krystexxa (pegloticase); Savient Pharma; For the treatment of chronic gout (hyperuricemia), Approved September 2010

Vimovo (naproxen + esomeprazole); AstraZeneca; For the treatment of arthritis in patients at risk for NSAID-associated ulcers, Approved April 2010

Drugs Approved in 2009

Cimzia (certolizumab pegol); UCB; For the treatment of rheumatoid arthritis, Approved May of 2009

Colcrys (colchicine); Mutual Pharmaceuticals; For gout flares and familial Mediterranean fever, Approved October 2009

Pennsaid (diclofenac sodium topical solution); Nuvo Research; For the treatment of osteoarthritis of the knee, Approved November 2009

Simponi (golimumab); Centocor Ortho Biotech; For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009

Stelara (ustekinumab); Janssen Biotech; For the treatment of plaque psoriasis, psoriatic arthritis and Crohn’s disease, Approved September 2009

Uloric (febuxostat); Takeda; For the treatment of chronic hyperuricemia in patients with gout, Approved February 2009

Drugs Approved in 2008

Orencia (abatacept); Bristol-Myers Squibb; For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008

Drugs Approved in 2006

Elaprase (idursulfase); Shire Pharmaceuticals; For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006

Rituxan (rituximab); Biogen IDEC, Genentech; For the treatment of moderately-to severely-active rheumatoid arthritis, Approved February 2006

Drugs Approved in 2005

Orencia (abatacept); Bristol-Myers Squibb; For the Treatment of Rheumatoid Arthritis, Approved December 2005

Drugs Approved in 2004

Vioxx (rofecoxib); Merck; For the treatment of rheumatoid arthritis, Approved April 2002 — UPDATED: WITHDRAWN OCTOBER 2004

Drugs Approved in 2002

Enbrel (etanercept); Immunex; For the treatment of psoriatic arthritis, Approved January 2002

Humira (adalimumab); Abbott Laboratories; For the treatment of moderately to severely active rheumatoid arthritis, Approved December 2002

Remicade (infliximab); Centocor Ortho Biotech; Intravenous infusion for the treatment of rheumatoid arthritis, Approved February 2002

Drugs Approved in 2001

Bextra; Pharmacia, Pfizer; Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain, Approved November 2001

Kineret; Amgen; Injectable therapy for the treatment of rheumatoid arthritis, Approved November 2001

Remicade (infliximab); Centocor Ortho Biotech; For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001

Supartz; Smith & Nephew Orthopaedics; Joint fluid therapy for treatment of osteoarthritis in the knee, Approved January 2001

Drugs Approved in 2000

Mobic (meloxicam) Tablets; Boehringer Ingelheim; For relief of the signs and symptoms of osteoarthritis, Approved April 2000

Vivelle (estradiol transdermal system); Novartis; For the prevention of postmenopausal osteoporosis, Approved August 2000

Drugs Approved in 1999

Lodine XL (etodolac); Wyeth; Treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis, Approved May 1999

Drugs Approved in 1998

Arava; Hoechst Marion Roussel; Treatment for Rheumatoid Arthritis, Approved September 1998

Lodine XL (etodolac); Wyeth; Treatment for arthritis, Approved February 1998

Salagen Tablets; MGI Pharma; Treatment for Sjogren’s Syndrome, Approved February 1998

Drugs Approved in 1997

Arthrotec; Searle; Treatment for arthritis, Approved December 1997

Etodolac; Royce Laboratories; Generic equivalent of Lodine, Approved December 1997

Etodolac; Royce Laboratories; Generic equivalent of Lodine, Approved April 1997

Ketoprofen; Schein Pharmaceutical; Generic equivalent or Oruvail, Approved December 1997

Synvisc, Synvisc-One (Hylan GF 20); Genzyme; For the treatment of pain associated with osteoarthritis of the knee, Approved August 1997

Tolmetin Sodium; Teva Pharmaceutical; Treatment for arthritis, Approved March 1997

Drugs Approved in 1996

Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996

Lodine (etodolac); Wyeth; Treatment for rheumatoid arthritis, Approved July 1996

Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth; Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996

These drugs are distributed in Richmondhill by:Dr. Pooneh Akhavan